An Insight Into the Cancer Stem Cell Survival Pathways Involved in Chemoresistance in Triple-Negative Breast Cancer

References

• Sung H , FerlayJ, SiegelRLet al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Perou CM , SørlieT, EisenMBet al. Molecular portraits of human breast tumours. Nature406(6797), 747–752 (2000).
   PubMed Web of Science ®Google Scholar
• Sørlie T , PerouCM, TibshiraniRet al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA98(19), 10869–10874 (2001).
   PubMed Web of Science ®Google Scholar
• Sotiriou C , NeoSY, McShaneLMet al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA100(18), 10393–10398 (2003).
   PubMed Web of Science ®Google Scholar
• Siegel Rl , MillerKD, JemalA. Cancer statistics. CA Cancer J. Clin.69(1), 7–34 (2019).
   PubMed Web of Science ®Google Scholar
• Keegan TH , KurianAW, GaliKet al. Racial/ethnic and socioeconomic differences in short-term breast cancer survival among women in an integrated health system. Am. J. Public Health105(5), 938–946 (2015).
   PubMed Web of Science ®Google Scholar
• Iwata H , ImSeock-Ah, MasudaNet al. PALOMA-3: Phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine-therapy – safety and efficacy in Asian patients. J. Glob. Oncol.3(4), 289–303 (2017).
   PubMed Web of Science ®Google Scholar
• Vagia E , MahalingamD, CistofanilliM. The landscape of targeted therapies in TNBC. Cancers (Basel)12(4), 916 (2020).
   PubMed Web of Science ®Google Scholar
• Lebert JM , LesterR, PowellEet al. Advances in the systemic treatment of triple-negative breast cancer. Curr. Oncol.25(Suppl. 1), S142–S150 (2018).
   PubMed Web of Science ®Google Scholar
• Liedtke C , MazouniC, HessKRet al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol.26(8), 1275–1281 (2008).
   PubMed Web of Science ®Google Scholar
• Carey LA , DeesE, SawyerLet al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res.13(8), 2329–2334 (2007).
   PubMed Web of Science ®Google Scholar
• Li X , LewisMT, HuangJet al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl Cancer Inst.100(9), 672–679 (2008).
   PubMedGoogle Scholar
• Zhou L , JiangY, YanTet al. The prognostic role of cancer stem cells in breast cancer: a meta-analysis of published literatures. Breast Cancer Res. Treat.122(3), 795–801 (2010).
   PubMed Web of Science ®Google Scholar
• Zou P , YoshiharaH, HosokawaKet al. p57Kip2 and p27Kip1 cooperate to maintain hematopoietic stem cell quiescence through interactions with Hsc70. Cell Stem Cell9(3), 247–261 (2011).
   PubMed Web of Science ®Google Scholar
• Wang T , FahrmannJF, LeeHet al. JAK/STAT3-regulated fatty acid β-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance. Cell Metab.27(1), 136–150 (2018).
   PubMed Web of Science ®Google Scholar
• Pires BRB , DeAmorim ÍSS, SouzaLDE, RodriguesJA, MencalhaAL. Targeting cellular signaling pathways in breast cancer stem cells and its implication for cancer treatment. Anticancer Res.36(11), 5681–5691 (2016).
   PubMed Web of Science ®Google Scholar
• Cochrane CR , SzczepnyA, WatkinsDN, CainJE. Hedgehog signaling in the maintenance of cancer stem cells. Cancers (Basel)7(3), 1554–1585 (2015).
   PubMed Web of Science ®Google Scholar
• Wicking C , McglinnE. The role of hedgehog signalling in tumorigenesis. Cancer Lett.173(1), 1–7 (2001).
   PubMed Web of Science ®Google Scholar
• Dontu G , JacksonKW, McnicholasE, KawamuraMJ, AbdallahWM, WichaMS. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res.6(6), 1–11 (2004).
   PubMed Web of Science ®Google Scholar
• Gupta PB , OnderTT, JiangGet al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell138(4), 645–659 (2009).
   PubMed Web of Science ®Google Scholar
• Talukdar S , BhoopathiP, EmdadL, DasS, SarkarD, FisherPB. Dormancy and cancer stem cells: an enigma for cancer therapeutic targeting. Adv. Cancer Res.141, 43–84 (2019).
   PubMed Web of Science ®Google Scholar
• Ko CCH , ChiaWK, SelvarajahGT, CheahYK, WongYP, TanGC. The role of breast cancer stem cell-related biomarkers as prognostic factors. Diagnostics10(9), 721 (2020).
   Web of Science ®Google Scholar
• Song K , FarzanehM. Signaling pathways governing breast cancer stem cells behavior. Stem Cell. Res. Ther.12(1), 1–11 (2021).
   PubMed Web of Science ®Google Scholar
• Liu X , GaoJ, SunYet al. Mutation of N-linked glycosylation in EpCAM affected cell adhesion in breast cancer cells. Biol. Chem.398(10), 1119–1126 (2017).
   PubMed Web of Science ®Google Scholar
• Liu M , LiuY, DengLet al. Transcriptional profiles of different states of cancer stem cells in triple-negative breast cancer. Mol. Cancer17(1), 1–6 (2018).
   PubMedGoogle Scholar
• Aponte PM , CaicedoA. Stemness in cancer: stem cells, cancer stem cells, and their microenvironment. Stem Cells Int.2017, 5619472 (2017).
   PubMed Web of Science ®Google Scholar
• Park S-Y , ChoiJ-H, NamJ-S. Targeting cancer stem cells in triple-negative breast cancer. Cancers (Basel)11(7), 965 (2019).
   PubMed Web of Science ®Google Scholar
• Longley DB , JohnstonPG. Molecular mechanisms of drug resistance. J. Pathol.205(2), 275–292 (2005).
   PubMed Web of Science ®Google Scholar
• Gottesman MM , PastanI. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem.62, 385–427 (1993).
   PubMed Web of Science ®Google Scholar
• Lobo NA , ShimonoY, QianD, ClarkeMF. The biology of cancer stem cells. Annu. Rev. Cell Dev. Biol.23, 675–699 (2007).
   PubMed Web of Science ®Google Scholar
• Yamada A , IshikawaT, OtaIet al. High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival. Breast Cancer Res. Treat.137(3), 773–782 (2013).
   PubMed Web of Science ®Google Scholar
• Xu L , ZhaoZ, WangKet al. Expression of aldehyde dehydrogenase 1 and ATP-binding cassette superfamily G member 2 is enhanced in primary foci and metastatic lymph node from patients with triple-negative breast cancer. Biomed. Res.28, 5078–5083 (2017).
   Google Scholar
• Chen Z , ShiT, ZhangL. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett.370(1), 153–164 (2016).
   PubMed Web of Science ®Google Scholar
• Sissung TM , BaumC, KirklandCT, GaoR, GardnerER, FiggWD. Pharmacogenetics of membrane transporters: an update on current approaches. Mol. Biotechnol.44(2), 152–167 (2010).
   PubMed Web of Science ®Google Scholar
• Oguri T , BesshoY, AchiwaHet al. MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol. Cancer Ther.6(1), 122–127 (2007).
   PubMed Web of Science ®Google Scholar
• Degorter MK , XiaCQ, YangJJ, KimRB. Drug transporters in drug efficacy and toxicity. Annu. Rev. Pharmacol. Toxicol.52, 249–273 (2012).
   PubMed Web of Science ®Google Scholar
• Goodell MA , BroseK, ParadisG, ConnerAS, MulliganRC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med.183(4), 1797–1806 (1996).
   PubMed Web of Science ®Google Scholar
• Chuthapisith S , EreminJ, El-SheemeyM, EreminO. Breast cancer chemoresistance: emerging importance of cancer stem cells. 19(1), 27–32 (2010).
   Google Scholar
• Scharenberg CW , HarkeyMA, Torok-StorbB. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood99(2), 507–512 (2002).
   PubMed Web of Science ®Google Scholar
• Saxena M , StephensMA, PathakH, RangarajanA. Transcription factors that mediate epithelial–mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis.2(7), e179(2011).
   PubMedGoogle Scholar
• Britton KM , EyreR, HarveyIJet al. Breast cancer, side population cells and ABCG2 expression. Cancer Lett.323(1), 97–105 (2012).
   PubMed Web of Science ®Google Scholar
• Arumugam A , SubramaniR, NandySBet al. Silencing growth hormone receptor inhibits estrogen receptor negative breast cancer through ATP-binding cassette sub-family G member 2. Exp. Mol. Med.51(1), 1–13 (2019).
   PubMedGoogle Scholar
• Guestini F , OnoK, MiyashitaMet al. Impact of topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res. Treat.173(2), 275–288 (2019).
   PubMed Web of Science ®Google Scholar
• Hawley TS , RizI, YangWet al. Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am. J. Hematol.88(4), 265–272 (2013).
   PubMed Web of Science ®Google Scholar
• Mcintosh K , CurtB, TiwariAK. Tackling multidrug resistance mediated by efflux transporters in tumor-initiating cells. Expert Opin. Drug Metab. Toxicol.12(6), 633–644 (2016).
   PubMed Web of Science ®Google Scholar
• Li Shi-Yong , SunR, WangHXet al. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells. J. Control. Release205, 7–14 (2015).
   PubMed Web of Science ®Google Scholar
• Habib JG , O'ShaughnessyJA. The hedgehog pathway in triple‐negative breast cancer. Cancer medicine5(10), 2989–3006 (2016).
   PubMed Web of Science ®Google Scholar
• Hamed AR , Abdel-AzimNS, ShamsKA, HammoudaFM. Targeting multidrug resistance in cancer by natural chemosensitizers. Bull. Natl Res. Cent.43, 8 (2019).
   Google Scholar
• Dohse M , ScharenbergC, ShuklaSet al. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab. Dispos.38(8), 1371–1380 (2010).
   PubMed Web of Science ®Google Scholar
• Shi Z , PengXX, KimIWet al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP binding cassette subfamily G member 2-mediated drug resistance. Cancer Res.67(22), 11012–11020 (2007).
   PubMed Web of Science ®Google Scholar
• Dai Cl , TiwariAK, WuCPet al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res.68(19), 7905–7914 (2008).
   PubMed Web of Science ®Google Scholar
• Tiwari AK , SodaniK, WangSRet al. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem. Pharmacol.78(2), 153–161 (2009).
   PubMed Web of Science ®Google Scholar
• Sims JT , GangulySS, BennettH, FriendJW, TepeJ, PlattnerR. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-kappaB and HSP27/p38/AKT pathways and by inhibiting ABCB1. PLoS ONE8(1), e55509 (2013).
   PubMed Web of Science ®Google Scholar
• Tabernero J , ShapiroGI, LorussoPMet al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov.3(4), 406–417 (2013).
   PubMed Web of Science ®Google Scholar
• Xie N , MouL, YuanJet al. Modulating drug resistance by targeting BCRP/ABCG2 using retrovirus-mediated RNA interference. PLoS ONE9(7), e103463(2014).
   PubMed Web of Science ®Google Scholar
• Hu J , LiJ, YueXet al. Targeting BCRP/ABCG2 by RNA interference enhances the chemotherapy sensitivity of human colon cancer side population cells. J. Huazhong Univ. Sci. Technol. Med. Sci.37, 231–236 (2017).
   PubMedGoogle Scholar
• Su Z , LiuG, FangTet al. Silencing MRP1–4 genes by RNA interference enhances sensitivity of human hepatoma cells to chemotherapy. Am. J. Transl. Res8(6), 2790–2802 (2016).
   PubMed Web of Science ®Google Scholar
• Wang Y , ZhaoL, XiaoQet al. miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells. Gynecol. Oncol.141( 3), 592–601 (2016).
   PubMed Web of Science ®Google Scholar
• Riddle RD , JohnsonRL, LauferE, TabinC. Sonic hedgehog mediates the polarizing activity of the ZPA. Cell75(7), 1401–1416 (1993).
   PubMed Web of Science ®Google Scholar
• Dessaud E , McMahonAP, BriscoeJ. Pattern formation in the vertebrate neural tube: a sonic hedgehog morphogen-regulated transcriptional network. Development135(15), 2489–2503 (2008).
   PubMed Web of Science ®Google Scholar
• Machold R , HayashiS, RutlinMet al. Sonic hedgehog is required for progenitor cell maintenance in telencephalic stem cell niches. Neuron39(6), 937–950 (2003).
   PubMed Web of Science ®Google Scholar
• Bhardwaj G , MurdochB, WuDet al. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat. Immunol.2(2), 172–180 (2001).
   PubMed Web of Science ®Google Scholar
• Skoda AM , SimovicD, KarinV, KardumV, VranicS, SermanL. The role of the Hedgehog signaling pathway in cancer: a comprehensive review. Bosn. J. Basic Med. Sci.18(1), 8–20 (2018).
   PubMed Web of Science ®Google Scholar
• Alexandre C , JacintoA, InghamPW. Transcriptional activation of hedgehog target genes in Drosophila is mediated directly by the cubitus interruptus protein, a member of the GLI family of zinc finger DNA-binding proteins. Genes Dev.10(16), 2003–2013 (1996).
   PubMed Web of Science ®Google Scholar
• Ruppert JM , KinzlerKW, WongAJet al. The GLI-Kruppel family of human genes. Mol. Cell. Biol.8(8), 3104–3113 (1988).
   PubMed Web of Science ®Google Scholar
• Sasaki H , NishizakiY, HuiC, NakafukuM, KondohH. Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain: implication of Gli2 and Gli3 as primary mediators of Shh signaling. Development126(17), 3915–3924 (1999).
   PubMed Web of Science ®Google Scholar
• Ramaswamy B , LuY, TengKet al. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Res.72(19), 5048–5059 (2012).
   PubMed Web of Science ®Google Scholar
• Sun Y , WangY, FanCet al. Estrogen promotes stemness and invasiveness of ER-positive breast cancer cells through Gli1 activation. Mol. Cancer Ther.13, 137 (2014).
   Google Scholar
• Thomas ZI , GibsonW, SextonJZet al. Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration. Br. J. Cancer104(10), 1575–1586 (2011).
   PubMed Web of Science ®Google Scholar
• Goel HL , PursellB, ChangCet al. GLI1 regulates a novel neuropilin-2/α6β1 integrin based autocrine pathway that contributes to breast cancer initiation. EMBO Mol. Med.5( 4), 488–508 (2013).
   PubMed Web of Science ®Google Scholar
• Harris LG , PannellLK, SinghS, SamantRS, ShevdeLA. Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of CYR61. Oncogene31(28), 3370–3380 (2012).
   PubMed Web of Science ®Google Scholar
• Colavito SA , ZouMR, YanQ, NguyenDX, SternDF. Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway. Breast Cancer Res. Treat.16(5), 444 (2014).
   Google Scholar
• Johnson RW , NguyenMP, PadaleckiSSet al. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res.71(3), 822–831 (2011).
   PubMed Web of Science ®Google Scholar
• Das S , SamantRS, ShevdeLA. Nonclassical activation of Hedgehog signaling enhances multidrug resistance and makes cancer cells refractory to Smoothened-targeting Hedgehog inhibition. J. Biol. Chem.288(17), 11824–11833 (2013).
   PubMed Web of Science ®Google Scholar
• O’Toole SA , MachalekDA, ShearerRFet al. Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Cancer Res.71(11), 4002–4014 (2011).
   PubMed Web of Science ®Google Scholar
• Kwon YJ , HurstDR, StegADet al. Gli1 enhances migration and invasion via up-regulation of MMP-11 and promotes metastasis in ERα negative breast cancer cell lines. Clin. Exp. Metastasis28(5), 437–449 (2011).
   PubMed Web of Science ®Google Scholar
• Cao X , GeradtsJ, DewhirstMW, LoHW. Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells. Oncogene31(1), 104–115 (2012).
   PubMed Web of Science ®Google Scholar
• Liu S , DontuG, MantleIDet al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res.66(12), 6063–6071 (2006).
   PubMed Web of Science ®Google Scholar
• Sims-Mourtada J , OpdenakerLM, DavisJ, ArnoldKM, FlynnD. Taxane-induced hedgehog signaling is linked to expansion of breast cancer stem-like populations after chemotherapy. Mol. Carcinog.54(11), 1480–1493 (2015).
   PubMed Web of Science ®Google Scholar
• Lei J , FanL, WeiGet al. Gli-1 is crucial for hypoxia-induced epithelial-mesenchymal transition and invasion of breast cancer. Tumour Biol.36(4), 3119–3126 (2015).
   PubMedGoogle Scholar
• Arnold KM , PohligRT, Sims-MourtadaJ. Co-activation of Hedgehog and Wnt signaling pathways is associated with poor outcomes in triple negative breast cancer. Oncol. Lett.14(5), 5285–5292 (2017).
   PubMed Web of Science ®Google Scholar
• Han B , QuY, JinYet al. FOXC1 activates Smoothened-independent Hedgehog signaling in basal-like breast cancer. Cell Rep.13(5), 1046–1058 (2015).
   PubMed Web of Science ®Google Scholar
• Sekulic A , MigdenMR, OroAEet al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N. Engl. J. Med.366(23), 2171–2179 (2012).
   PubMed Web of Science ®Google Scholar
• Robinson GW , OrrBA, WuGet al. Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: results from Phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032. J. Clin. Oncol.33(24), 2646–2654 (2015).
   PubMed Web of Science ®Google Scholar
• Bhateja P , CherianM, MajumderS, RamaswamyB. The Hedgehog signaling pathway: a viable target in breast cancer?Cancers (Basel)11(8), 1126 (2019).
   PubMed Web of Science ®Google Scholar
• Koike Y , OhtaY, SaitohWet al. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells. Breast Cancer Res. Treat.24(5), 683–693 (2017).
   Google Scholar
• Clevers H , NusseR. Wnt/beta-catenin signaling and disease. Cell149(6), 1192–1205 (2012).
   PubMed Web of Science ®Google Scholar
• Staal FJ , LuisTC, TiemessenMM. WNT signalling in the immune system: WNT is spreading its wings. Nat. Rev. Immunol.8(8), 581–593 (2008).
   PubMed Web of Science ®Google Scholar
• Gieseck RL , WilsonMS, WynnTA. Type 2 immunity in tissue repair and fibrosis. Nat. Rev. Immunol.18(1), 62–76 (2018).
   PubMed Web of Science ®Google Scholar
• Ng LF , KaurP, BunnagNet al. WNT signaling in disease. Cells8(8), 826 (2019).
   PubMed Web of Science ®Google Scholar
• Khramtsov AI , KhramtsovaGF, TretiakovaM, HuoD, OlopadeOI, GossKH. Wnt/β-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am. J. Pathol.176(6), 2911–2920 (2010).
   PubMed Web of Science ®Google Scholar
• Geyer FC , Lacroix-TrikiM, SavageKet al. β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod. Pathol.24(2), 209–231 (2011).
   PubMed Web of Science ®Google Scholar
• Dey N , BarwickBG, MorenoCSet al. Wnt signaling in triple negative breast cancer is associated with metastasis. BMC Cancer13, 1 (2013).
   PubMed Web of Science ®Google Scholar
• Xu J , ProsperiJR, ChoudhuryN, OlopadeOI, GossKH. β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. PLoS ONE10(2), e0117097(2015).
   PubMed Web of Science ®Google Scholar
• Borg J-P , BelottiE, DaulatAet al. Deregulation of the non-canonical pathway in triple-negative breast cancer. FASEB J.27, 610–611 (2013).
   Web of Science ®Google Scholar
• Shen H , YanW, YuanJ, WangZ, WangC. Nek2B activates the Wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin. J. Exp. Clin. Cancer Res.38(1), 243 (2019).
   PubMedGoogle Scholar
• Fultang N , ChakrabortyM, PeethambaranB. Regulation of cancer stem cells in triple negative breast cancer. Cancer Drug Resistance4(2), 321–342 (2021).
   PubMedGoogle Scholar
• Gangrade A , PathakV, Augelli-SzafranCEet al. Preferential inhibition of Wnt/β-catenin signaling by novel benzimidazole compounds in triple-negative breast cancer. Int. J. Mol. Sci.19(5), 1524 (2018).
   PubMed Web of Science ®Google Scholar
• Gupta PB , OnderTT, JiangGet al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell138(4), 645–659 (2009).
   PubMed Web of Science ®Google Scholar
• Jang GB , HongIS, KimRJet al. Wnt/β-catenin small-molecule inhibitor CWP232228 preferentially inhibits the growth of breast cancer stem-like cells. Cancer Res.75(8), 1691–1702 (2015).
   PubMed Web of Science ®Google Scholar
• Johnson JP , KumarP, KoulnisM, PatelM, SiminK. Crucial and novel cancer drivers in a mouse model of triple-negative breast cancer. Cancer Genomics Proteomics11(3), 115–126 (2014).
   PubMed Web of Science ®Google Scholar
• Poulsen A , SooYH, WangWet al. Pharmacophore model for Wnt/Porcupine inhibitors and its use in drug design. J. Chem. Inf. Model.55(7), 1435–1448 (2015).
   PubMed Web of Science ®Google Scholar
• Langton PF , KakugawaS, VincentJP. Making, exporting, and modulating Wnts. Trends Cell Biol.26(10), 756–765 (2016).
   PubMed Web of Science ®Google Scholar
• Agarwal P , ZhangB, HoYet al. Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI. Blood129(8), 1008–1020 (2017).
   PubMed Web of Science ®Google Scholar
• Bhamra I , ArmerR, BinghamMet al. Porcupine inhibitor RXC004 enhances immune response in pre-clinical models of cancer. Cancer Res.78, Abstract 3764 (2018).
   Google Scholar
• Valenta T , HausmannG, BaslerK. The many faces and functions of beta-catenin. EMBO J.31(12), 2714–2736 (2012).
   PubMed Web of Science ®Google Scholar
• Fan Y , DuttaJ, GuptaN, FanG, GélinasC. Regulation of programmed cell death by NF-κB and its role in tumorigenesis and therapy. Adv. Exp. Med. Biol.615, 223–250 (2008).
   PubMed Web of Science ®Google Scholar
• Gupta SC , KimJH, PrasadS, AggarwalBB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metas. Rev.29(3), 405–434 (2010).
   PubMed Web of Science ®Google Scholar
• Td G . Multiple myeloma: lusting for NF-kappaB. Cancer Cell12(2), 95–97 (2007).
   PubMed Web of Science ®Google Scholar
• Ossovskaya V , WangY, BudoffAet al. Exploring molecular pathways of triple-negative breast cancer. Genes Cancer2(9), 870–879 (2011).
   PubMedGoogle Scholar
• Fusella F , SeclìL, BussoEet al. The IKK/NF-κB signaling pathway requires Morgana to drive breast cancer metastasis. Nat. Commun.8(1), 1636 (2017).
   PubMedGoogle Scholar
• Chaturvedi MM , SungB, YadavVR, KannappanR, AggarwalBB. NF-kappaB addiction and its role in cancer: ‘one size does not fit all’. Oncogene30(14), 1615–1630 (2011).
   PubMed Web of Science ®Google Scholar
• Hossain F , SorrentinoC, UcarDAet al. Notch signaling regulates mitochondrial metabolism and NF-κB activity in triple-negative breast cancer cells via IKKα-dependent non-canonical pathways. Front. Oncol.8, 575 (2018).
   PubMed Web of Science ®Google Scholar
• Kim T , YangS-J, HwangDet al. A basal-like breast cancer-specific role for SRF–IL6 in YAP-induced cancer stemness. Nat. Comm.6(1), 1–15 (2015).
   Google Scholar
• Barbie TU , AlexeG, ArefARet al. Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J. Clin. Invest.124(12), 5411–5423 (2014).
   PubMed Web of Science ®Google Scholar
• Messeha SS , ZarmouhNO, MendoncaP, AlwagdaniH, KoltaMG, SolimanKFA. The inhibitory effects of plumbagin on the NF-κB pathway and CCL2 release in racially different triple-negative breast cancer cells. PLoS ONE13(7), 1–25 (2018).
   Web of Science ®Google Scholar
• Erkel G , AnkeT, SternerO. Inhibition of NF-κB activation by panepoxydone. Biochem. Biophys. Res. Commun.226(1), 214–221 (1996).
   PubMed Web of Science ®Google Scholar
• Pan H , ZhouW, HeWet al. Genistein inhibits MDA-MB-231 triple-negative breast cancer cell growth by inhibiting NF-κB activity via the Notch-1 pathway. Int. J. Mol. Med.30(2), 337–343 (2012).
   PubMed Web of Science ®Google Scholar
• Degraffenried LA , ChandrasekarB, FriedrichsWEet al. NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann. Oncol.15(6), 885–890 (2004).
   PubMed Web of Science ®Google Scholar
• Aster JC , PearWS, BlacklowSC. The varied roles of Notch in cancer. Annu. Rev. Pathol. Mech. Dis.12, 245–275 (2017).
   PubMed Web of Science ®Google Scholar
• Ranganathan P , WeaverKL, CapobiancoAJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat. Rev. Cancer11(5), 338–351 (2011).
   PubMed Web of Science ®Google Scholar
• Takebe N , NguyenD, YangSX. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol. Ther.141(2), 140–149 (2014).
   PubMed Web of Science ®Google Scholar
• Andersson ER , LendahlU. Therapeutic modulation of Notch signalling–are we there yet?Nat. Rev. Drug Discov.13(5), 357–378 (2014).
   PubMed Web of Science ®Google Scholar
• Takebe N , MieleL, HarrisPJet al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat. Rev. Clin. Oncol.12(8), 445–464 (2015).
   PubMed Web of Science ®Google Scholar
• Espinoza I , MieleL. Notch inhibitors for cancer treatment. Pharmacol. Ther.139(2), 95–110 (2013).
   PubMed Web of Science ®Google Scholar
• Rustighi A , ZanniniA, TiberiLet al. Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast. EMBO Mol. Med.6(1), 99–119 (2014).
   PubMed Web of Science ®Google Scholar
• Harrison H , FarnieG, HowellSJet al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res.70(2), 709–718 (2010).
   PubMed Web of Science ®Google Scholar
• Weng AP , FerrandoAA, LeeW. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science306(5694), 269–271 (2004).
   PubMed Web of Science ®Google Scholar
• Wang K , ZhangQ, LiDet al. PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a gamma-secretase inhibitor. Clin. Cancer Res.21(6), 1487–1496 (2015).
   PubMed Web of Science ®Google Scholar
• Zhu H , BhaijeeF, IshaqNet al. Correlation of Notch1, pAKT and nuclear NF-kappaB expression in triple negative breast cancer. Am. J. Cancer Res.3(2), 230–239 (2013).
   PubMed Web of Science ®Google Scholar
• Pan H , ZhouW, HeWet al. Genistein inhibits MDA-MB-231 triple-negative breast cancer cell growth by inhibiting NF-κB activity via the Notch-1 pathway. Int. J. Mol. Med.30(2), 337–343 (2012).
   PubMed Web of Science ®Google Scholar
• Qiu M , PengQ, JiangIet al. Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells. Cancer Lett.328(2), 261–270 (2013).
   PubMed Web of Science ®Google Scholar
• Mittal S , SharmaA, BalajiSAet al. Coordinate hyperactivation of Notch1 and Ras/MAPK pathways correlates with poor patient survival: novel therapeutic strategy for aggressive breast cancers. Mol. Cancer Ther.13(12), 3198–3209 (2014).
   PubMed Web of Science ®Google Scholar
• Boelens MC , WuTJ, NabetBYet al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell159(3), 499–513 (2014).
   PubMed Web of Science ®Google Scholar
• Zhang X , LiuX, LuoJet al. Notch3 inhibits epithelial–mesenchymal transition by activating Kibra-mediated Hippo/YAP signaling in breast cancer epithelial cells. Oncogenesis5, e269 (2016).
   PubMed Web of Science ®Google Scholar
• Giuli MV , GiulianiE, ScrepantiI, BellaviaD, ChecquoloS. Notch signaling activation as a hallmark for triple-negative breast cancer subtype. Journal of oncology (2019).
   PubMed Web of Science ®Google Scholar
• Guo S , LiuM, Gonzalez-PerezRR. Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim. Biophys. Acta1815(2), 197–213 (2011).
   PubMed Web of Science ®Google Scholar
• Checquolo S , PalermoR, CialfiSet al. Differential subcellular localization regulates c-Cbl E3 ligase activity upon Notch3 protein in T-cell leukemia. Oncogene29(10), 1463–1474 (2010).
   PubMed Web of Science ®Google Scholar
• Cialfi S , PalermoR, MancaSet al. Glucocorticoid sensitivity of T-cell lymphoblastic leukemia/lymphoma is associated with glucocorticoid receptor-mediated inhibition of Notch1 expression. Leukemia27(2), 485–488 (2013).
   PubMed Web of Science ®Google Scholar
• Franciosa G , DiluvioG, GaudioFDet al. Prolyl-isomerase Pin1 controls Notch3 protein expression and regulates T-ALL progression. Oncogene35(36), 4741–4751 (2016).
   PubMed Web of Science ®Google Scholar
• Locatelli MA , AftimosP, DeesECet al. Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer. Oncotarget8(2), 2320–2328 (2017).
   PubMedGoogle Scholar
• Schott AF , LandisMD, DontuGet al. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin. Cancer Res19(6), 1512–1524 (2013).
   PubMed Web of Science ®Google Scholar
• Broner EC , AlpertG, GluschnaiderUet al. AL101 mediated tumor inhibition in notch-altered TNBC PDX models. J. Clin. Oncol.37(Suppl. 15), Abstract 1064 ( 2019).
   Web of Science ®Google Scholar
• Smith DC , ChughR, PatnaikAet al. A Phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors. Invest. New Drugs37( 4), 722–730 (2019).
   PubMed Web of Science ®Google Scholar
• Rosen LS , WesolowskiR, BaffaRet al. A Phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors. Invest. New Drugs38(1), 120–130 (2019).
   PubMed Web of Science ®Google Scholar
• Camargo FD , GokhaleS, JohnnidisJBet al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr. Biol.17(23), 2054–2060 (2007).
   PubMed Web of Science ®Google Scholar
• Pan D . Hippo signaling in organ size control. Genes Dev.21(8), 886–897 (2007).
   PubMed Web of Science ®Google Scholar
• Vlug EJ , vande Ven RAH, VermeulenJF, BultP, Van DiestPJ, DerksenPWB. Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer. Cell. Oncol.36(5), 375–384 (2013).
   PubMed Web of Science ®Google Scholar
• Kim HM , JungW, KooJS. Expression of Yes-associated protein (YAP) in metastatic breast cancer. Int. J. Clin. Exp. Pathol.8(9), 11248–11257 (2015).
   PubMed Web of Science ®Google Scholar
• Zhao Y , KhanalP, SavageP, SheYM, CyrTD, YangX. YAP-induced resistance of cancer cells to antitubulin drugs is modulated by a Hippo-independent pathway. Cancer Res.74(16), 4493–4503 (2014).
   PubMed Web of Science ®Google Scholar
• Sulaiman A , McGarryS, El-SahliSet al. Co-targeting bulk tumor and CSCs in clinically translatable TNBC patient-derived xenografts via combination nanotherapy. Mol. Cancer Ther.18(10), 1755–1764 (2019).
   PubMed Web of Science ®Google Scholar
• Zhao B , LiL, GuanKl. Hippo signalling at a glance. Cell Sci123(23), 4001–4006 (2010).
   PubMed Web of Science ®Google Scholar
• Barry ER , CamargoFD. The Hippo superhighway: signalling cross roads converging on the Hippo/Yap pathway in stem cells and development. Curr. Opin. Cell Biol.25(2), 247–253 (2013).
   PubMed Web of Science ®Google Scholar
• Varelas X . The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development141(8), 1614–1626 (2014).
   PubMed Web of Science ®Google Scholar
• Yu FX , MengZ, PlouffeSW, GuanKl. Hippo pathway regulation of gastrointestinal tissues. Annu. Rev. Physiol.77, 201–227 (2014).
   PubMed Web of Science ®Google Scholar
• Moroishi T , HansenCG, GuanKl. The emerging roles of YAP and TAZ in cancer. Nat. Rev. Cancer15(2), 73–79 (2015).
   PubMed Web of Science ®Google Scholar
• Piccolo S , DupontS, CordenonsiM. The biology of YAP/TAZ: Hippo signalling and beyond. Physiol. Rev.94(4), 1287–1312 (2014).
   PubMed Web of Science ®Google Scholar
• Atkins M , PotierD, RomanelliLet al. An ectopic network of transcription factors regulated by Hippo signaling drives growth and invasion of a malignant tumor model. Curr. Biol.26(16), 2101–2113 (2016).
   PubMed Web of Science ®Google Scholar
• Vici P , ErcolaniC, DiBenedetto Aet al. Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy. J. Exp. Clin. Cancer Res.35, 62 (2016).
   PubMed Web of Science ®Google Scholar
• Maugeri-Saccà M , DeMaria R. Hippo pathway and breast cancer stem cells. Critical reviews in oncology/hematology. 99, 115–122 (2016).
   PubMed Web of Science ®Google Scholar
• Vuoriluoto K , HaugenH, KiviluotoSet al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene30(12), 1436–1448 (2011).
   PubMed Web of Science ®Google Scholar
• Virtakoivu R , MaiA, MattilaEet al. Vimentin–ERK signaling uncouples Slug gene regulatory function. Cancer Res.75(11), 2349–2362 (2015).
   PubMed Web of Science ®Google Scholar
• Song S , HonjoS, JinJet al. The Hippo coactivator YAP1 mediatesEGFR overexpression and confers chemoresistance in esophageal cancer. Clin. Cancer Res.21(11), 2580–2590 (2015).
   PubMed Web of Science ®Google Scholar
• Mao B , HuF, ChengJet al. SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma. Oncogene33(11), 1468–1474 (2014).
   PubMed Web of Science ®Google Scholar
• Xia Y , ZhangYL, YuC, ChangT, FanHY. YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells. PLoS ONE9(11), e109575 (2014).
   PubMed Web of Science ®Google Scholar
• Huo X , ZhangQ, LiuAMet al. Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma. Oncol. Rep.29(2), 840–846 (2013).
   PubMed Web of Science ®Google Scholar
• Cheng H , ZhangZ, Rodriguez-BarruecoRet al. Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells. Oncotarget7(20), 28976–28988 (2016).
   PubMedGoogle Scholar
• Fernandez-L A , SquatritoM, NorthcottPet al. Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. Oncogene31(15), 1923–1937 (2012).
   PubMed Web of Science ®Google Scholar
• Tsujiura M , MazackV, SudolMet al. Yes-associated protein (YAP) modulates oncogenic features and radiation sensitivity in endometrial cancer. PLoS ONE9(6), e100974 (2014).
   PubMed Web of Science ®Google Scholar
• Andrade D , MehtaM, GriffithJet al. YAP1 inhibition radiosensitizes triple negative breast cancer cells by targeting the DNA damage response and cell survival pathways. Oncotarget8(58), 98495 (2017).
   PubMedGoogle Scholar
• Jiao S , WangH, ShiZet al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell25(2), 166–180 (2014).
   PubMed Web of Science ®Google Scholar
• Sorrentino G , RuggeriN, SpecchiaVet al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat. Cell Biol.16(4), 357–366 (2014).
   PubMed Web of Science ®Google Scholar
• Wang C , ZhuX, FengWet al. Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm. Am. J. Cancer Res.6(1), 27–37 (2015).
   PubMed Web of Science ®Google Scholar
• Oku Y , NishiyaN, ShitoTet al. Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers. FEBS Open Bio5(1), 542–549 (2015).
   PubMed Web of Science ®Google Scholar
• Moroishi T , HayashiT, PanWWet al. The Hippo pathway kinases LATS1/2 suppress cancer immunity. Cell167(6), 1525.e1517–1539.e1517 (2016).
   Web of Science ®Google Scholar
• Mittendorf EA , PhilipsA, MericbernstamFet al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol. Res.2(4), 361–370 (2014).
   PubMed Web of Science ®Google Scholar
• Schmid P , CruzC, BraitehFSet al. Atezolizumab in metastatic TNBC (mTNBC): long-term clinical outcomes and biomarker analyses. Cancer Res.77(Suppl. 13), Abstract 2986 (2017).
   Google Scholar
• Yang Y , LiX, WangT, GuoQ, XiT, ZhengL. Emerging agents that target signaling pathways in cancer stem cells. Journal of hematology & oncology13, 1–8 (2020).
   PubMed Web of Science ®Google Scholar
• Guanizo AC , FernandoCD, GaramaDJ, GoughDJ. STAT3: a multifaceted oncoprotein. Growth Factors36(1–2), 1–14 (2018).
   PubMed Web of Science ®Google Scholar
• Pollack V , SarkoziR, BankiZet al. Oncostatin M-induced effects on EMT in human proximal tubular cells: differential role of ERK signaling. Am. J. Physiol. Renal Physiol.293(5), F1714–F1726 (2007).
   PubMed Web of Science ®Google Scholar
• Junk DJ , BrysonBL, SmigielJM, ParameswaranN, BartelCA, JacksonMW. Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling. Oncogene36(28), 4001–4013 (2017).
   PubMed Web of Science ®Google Scholar
• Kucia-Tran JA , TulkkiV, SmithSet al. Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial mesenchymal transition and poor overall survival. Br. J. Cancer115(2), 212–222 (2016).
   PubMed Web of Science ®Google Scholar
• Smigiel JM , ParameswaranN, JacksonMW. Potent EMT and CSC phenotypes are induced by oncostatin-M in pancreatic cancer. Mol. Cancer Res.15(4), 478–488 (2017).
   PubMed Web of Science ®Google Scholar
• Yu ZJ , LiZ, WangCCet al. Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M. Gastric Cancer22(5), 955–966 (2019).
   PubMed Web of Science ®Google Scholar
• Sirkisoon SR , CarpenterRL, RimkusTet al. Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer. Oncogene37(19), 2502–2514 (2018).
   PubMed Web of Science ®Google Scholar
• Kuo WY , HwuL, WuCY, LeeJS, ChangCW, LiuRS. STAT3/NF-κB-regulated lentiviral TK/GCV suicide gene therapy for cisplatin-resistant triple-negative breast cancer. Theranostics7(3), 647–663 (2017).
   PubMed Web of Science ®Google Scholar
• Moreira MP , BragaL, CassaliGD, SilvaLM. STAT3 as a promising chemoresistance biomarker associated with the CD44+/high/CD24−/low/ALDH+ BCSCs-like subset of the triple-negative breast cancer (TNBC) cell line. Exp. Cell Res.363(2), 283–290 (2018).
   PubMed Web of Science ®Google Scholar
• Wang K , ZhuX, ZhangK, YinY, ChenY, ZhangT. Interleukin-6 contributes to chemoresistance in MDA-MB-231 cells via targeting HIF-1α. J. Biochem. Mol. Toxicol.32(3), 1–7 (2018).
   Web of Science ®Google Scholar
• Qin JJ , YanL, ZhangJ, ZhangWD. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. J. Exp. Clin. Cancer Res.38(1), 195 (2019).
   PubMedGoogle Scholar
• Vyas D , Lopez-HisijosN, ShahPet al. A second-generation proteasome inhibitor and doxorubicin modulates IL-6, pSTAT-3 and NF-kB activity in MDA-MB-231 breast cancer cells. J. Nanosci. Nanotechnol.17(1), 175–185 (2017).
   PubMed Web of Science ®Google Scholar
• Tian J , ChenX, FuSet al. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer. Breast Cancer Res. Treat.175(3), 553–566 (2019).
   PubMed Web of Science ®Google Scholar
• Fu S , ChenX, LoHW, LinJ. Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer. Cancer Lett.448, 11–19 (2019).
   PubMed Web of Science ®Google Scholar
• Aryappalli P , Al-QubaisiSS, AttoubSet al. The IL-6/STAT3 signaling pathway is an early target of Manuka honey induced suppression of human breast cancer cells. Front. Oncol.7, 167 (2017).
   PubMed Web of Science ®Google Scholar
• Rios-Fuller TJ , Ortiz-SotoG, Lacourt-VenturaMet al. Ganoderma lucidum extract (GLE) impairs breast cancer stem cells by targeting the STAT3 pathway. Oncotarget9(89), 35907–35921 (2018).
   PubMedGoogle Scholar
• Kim S , JeonM, LeeJ et al. Induction of fibronectin in response to epidermal growth factor is suppressed by silibinin through the inhibition of STAT3 in triple negative breast cancer cells. Oncol. Rep.32(5), 2230–2236 (2014).
   PubMed Web of Science ®Google Scholar
• Mehta R , KattaH, AlimirahFet al. Deguelin action involves c-met and EGFR signaling pathways in triple negative breast cancer cells. PLoS ONE8(6), e65113 (2013).
   PubMed Web of Science ®Google Scholar
• Chun J , ParkM, KoH, LeeK, KimYS. Bioassay-guided isolation of cantharidin from blister beetles and its anticancer activity through inhibition of epidermal growth factor receptor-mediated STAT3 and Akt pathways. J. Nat. Med.72(4), 937–945 (2018).
   PubMed Web of Science ®Google Scholar
• Yamashita N , KondoM, ZhaoSet al. Picrasidine G decreases viability of MDA-MB 468 EGFR-overexpressing triple-negative breast cancer cells through inhibition of EGFR/STAT3 signaling pathway. Bioorg. Med. Chem. Lett.27(11), 2608–2612 (2017).
   PubMed Web of Science ®Google Scholar
• Kim HS , HoangVH, HongMet al. Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents. Bioorg. Med. Chem.27(7), 1370–1381 (2019).
   PubMed Web of Science ®Google Scholar
• Cho TM , KimJY, KimYJet al. C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition. Cancer Lett.447, 141–153 (2019).
   PubMed Web of Science ®Google Scholar
• Tegowski M , FanC, BaldwinAS. Thioridazine inhibits self-renewal in breast cancer cells via DRD2-dependent STAT3 inhibition, but induces a G1 arrest independent of DRD2. J. Biol. Chem.293(41), 15977–15990 (2018).
   PubMed Web of Science ®Google Scholar
• Cheng CC , ShiLH, WangXJet al. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066. Int. J. Oncol.53, 339–348 (2018).
   PubMed Web of Science ®Google Scholar
• Chen Y , JiM, ZhangSet al. Bt354 as a new STAT3 signaling pathway inhibitor against triple negative breast cancer. J. Drug Target.26(10), 920–930 (2018).
   PubMed Web of Science ®Google Scholar
• Zhang W , YuW, CaiG et al. A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy. Cell Death Dis.9(11), 1098 (2018).
   PubMedGoogle Scholar